Practical implication
Clinical investigations must now include justification for DDM selection and ensure that DHTs are verified and validated to support their intended clinical role.
The FDA's joint paper emphasizes the importance of digitally derived measures (DDMs) in clinical investigations, ensuring they are evidence-based and fit for purpose. Key aspects include verification and validation requirements of DHTs and a focus on the meaningfulness of outcomes to patients, which influences safe and effective medical product development.
What changed: The FDA has introduced new requirements for the verification and validation of Digital Health Technologies used to generate Digitally Derived Measures (DDMs) in clinical investigations.
Why it matters: These guidelines standardize the collection of safety and efficacy data, facilitating continuous and real-time monitoring of adverse events, and improving the reliability of clinical outcomes derived from DHTs.
Practical implication: Clinical investigations must now include justification for DDM selection and ensure that DHTs are verified and validated to support their intended clinical role.
View original source
Published from the Firecrawl policy change extraction pipeline.